Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10599692
Filing Date	2006-10-05
First Named Inventor	Prediman K. Shah
Art Unit	1633
Examiner Name	Janet L. Epps Smith
Attorney Docket Number	67789-101US0

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10599692
Filing Date	2006-10-05
First Named Inventor	Prediman K. Shah
Art Unit	1633
Examiner Name	Janet L. Epps Smith
Attorney Docket Number	67789-101US0

	1	SETH, et al., "Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor," Mol. Cell. Biol. 4(8): 1528-1533 (1984).	☐
	2	SETH, et al., "Role of a low-pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxin-epidermal growth factor conjugate," J. Virol. 51 (3): 650-655 (1984).	☐
	3	SVENSSON, "Role of vesicles during adenovirus 2 internalization into HeLa cells," J. Virol. 55(2): 442-449 (1985).	☐
	4	TEIGER, et al., "Local gene delivery within the media of rabbit iliac arteries by using the infiltrator intramural delivery device ," J. Cardiovasc. Pharmacol. 33(5): 726-732 (1999).	☐
	5	TURUNEN, et al., "Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer," Mol. Ther. 6(3): 306 (2002).	☐
	6	VARGA, et al., "Infectious entry pathway of adenovirus type 2," J. Virol. 65(11): 6061-6070 (1991).	☐
	7	VERMA, "Retroviral vectors for gene transfer," in Microbiology"-1985 (Leive, ed.) American Society for Microbiology: Washington D.C., pp. 229-232 (1985).	☐
	8	WEISGRABER, et al., "A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins," J. Clin. Invest. 66: 901-907 (1980).	☐
	9	WICKHAM, et a1., "Integrins av~3 and av~5 promote adenovirus internalization but not virus attachment," Cell 73(2): 309-319 (1993).	☐
	10	WOLFF, et al., "Conditions affecting direct gene transfer into rodent muscle in vivo," BioTechniques 11(4): 474-485 (1991).	☐
	11	WOLFF, et al., "Direct gene transfer into mouse muscle in vivo," Science 247(4949): 1465-1468 (1990).	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10599692
	Filing Date	2006-10-05
	First Named Inventor	Prediman K. Shah
	Art Unit	1633
	Examiner Name	Janet L. Epps Smith
	Attorney Docket Number	67789-101US0

	12	ZABNER, et a1., "Safety and efficacy of repetitive adenovirus-mediated transfer of CFfR cDNA to airway epithelia of primates and cotton rats," Nat. Genet. 6(1): 75-83 (1994).	☐
	13	ZABNER, et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis," Cell 75(2): 207-216 (1993).	☐
	14	ZHANG, et al., "Generation and identification of recombinant adenovirus by liposomemediated transfection and PCR analysis" BioTechniques 15(5): 868-872 (1993).	☐
	15	GANDJINI, H. et al., Resistance to LDL oxidative modifications of an N-terminal apolipoprotein B epitope. Atherosclerosis 1991 89:83-93	☐
	16	CHAUHAN, et al., Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100. Biochemistry 1998 37:3735-3742	☐
	17	ZHOU, Xinghua et al., LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Atherosclerosis, Thrombosis And Vascular Biology 2001 Vol 21, No 1, pages 108-114	☐
	18	GEORGE, J et al., Hyperimmunization of ApoE-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998, vol 138, pages 147-152	☐
	19	PALIINSKI, W. et al., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proceedings of the National Academy of Sciences 1995, vol 92 pages 821-825	☐
	20	PALINSKI, W. et al., Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosclerosis 1990 vol 10, pages 324-335	☐
	21	ROSENFELD, M. E. et al. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severityfrom WHHL rabbits. Atherosclerosis 1990 vol 10 pages 336-349	☐
	22	LEFVERT, A K. Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies. Journal of Internal Medicine March 1, 2000 vol 247 pages 385-390	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10599692
	Filing Date	2006-10-05
	First Named Inventor	Prediman K. Shah
	Art Unit	1633
	Examiner Name	Janet L. Epps Smith
	Attorney Docket Number	67789-101US0

	23	DUNNING, A M. et al., Association between epitopes detected by monoclonal antibody BIP-45 and the xbal polymorphisms of apolipoprotein B. Clinical Genetics,January 1, 1998, vol 33 pages 181-188	☐
	24	YOUNG, Stephen G et al., Definition of a nonlinear conformational epitope for the apolipoprotein B-100 specific monoclonal antibody MB47 Journal of Lipid Research January 1, 1994 vol 35 pages 399-407	☐
	25	FREDRIKSON Gunilla Nordin et al., Inhibition of atherosclerosis in apo E null mice by imunization with native and MDA-modified apoB peptide sequences. Journal of the American College of Cardiology 2003 vol 39 page 240A	☐
	26	FREDRIKSON Gunilla Nordin et al., Atheroprotective immunization with MDA-modified apoB-100 peptide sequences is associated with activation of TH2 specific antibody expression Autoimmunity 2005 vol 38 pages 171-179	☐
	27	SHIH, Ing Lung et al., Focal accumulation of an apolipoprotein B-based synthetic oligopeptide in the healing rabbit arterial wall. Proceedings of the National Academy of Sciences 1990 vol 87 pages 1436-1440	☐
	28	CHEN S-H et al., Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon Science October 16, 1987 vol 238 pages 363-366	☐
	29	VALENTINOVA, N. V. et al., Immunoreactivity of Apolipoprotein B-100 in oxidatively modified low density lipoprotein. Biological Chemistry 1994 vol 375 pages 651-658	☐
	30	TAILLEUX, A et al., Immunological properties of ApoB-containing lipoprotein particles in human atherosclerotic arteries Journal of Lipid Research January 1, 1993 vol 34 pages 719-728	☐
	31	MCCORMICK et al., Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 92:10147-10151, 1995	☐
	32	PEASE et al., Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem 265(1): 553-568, 1990	☐
	33	MILNE et al., The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem 264(33): 19754-19760, 1989	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10599692
Filing Date	2006-10-05
First Named Inventor	Prediman K. Shah
Art Unit	1633
Examiner Name	Janet L. Epps Smith
Attorney Docket Number	67789-101US0

	34	WANG, et al., Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism. Arterioscler Thromb Vasc Biol 20: 1301-1308, 2000	☐
	35	SCHIOPU et al., Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110: 2047-2052, 2004	☐
	36	LATIF, et al., Liposomes in immunology. J Biosci 6(4): 491-502, 1984	☐
	37	WANG, Xiaosong et al., Comparative genetics of atherosclerosis and restenosis: exploration with mouse models, Arterioscler Thromb Vasc Biol., 22: June 2002 (http://www.atvbaha.org) pages 884-886.	☐
	38	HERZYK et al., Bochim Biophys Acta 922:145-154, 1987	☐
	39	CHEHIN et al., Early stages of LDL Oxidation: apolipoprotein B structural changes monitored by infrared spectroscopy. J Lipid Res 42: 778-782, 2001	☐
	40	BIELICKI, J.K. et al., Evidence that Apolipoprotein A-1 milane has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol, 1997, Arteriorscler. Thromb. Vasc. Biol., 17(9), pp. 1637-1643.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Janet Epps Smith/	Date Considered	03/26/2012

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./